Radim Vrzal | Molecular Biology | Best Researcher Award

Published on by Network Science

Prof. Dr. Radim Vrzal | Molecular Biology | Best Researcher Award

Palacky University in Olomouc | Czech Republic

Author Profiles

Scopus

Orcid ID

Early Academic Pursuits

Prof. Dr. Radim Vrzal began his academic journey with a Master’s degree in Biochemistry from the Institute of Chemical Technology in Prague (1998–2003). His academic excellence and research aptitude led him to pursue a Ph.D. in cotutelle between Palacký University, Olomouc, and INSERM, Montpellier, France, where he investigated biochemical mechanisms under expert international guidance. This early exposure to collaborative research set the foundation for his future contributions in molecular biology, pharmacology, and toxicology.

Professional Endeavors

He commenced his professional career as an Assistant Professor at the Institute of Medical Chemistry and Biochemistry, Palacký University, in 2006. His teaching and research responsibilities later expanded at the Department of Cell Biology and Genetics, where he has served as an Associate Professor since 2011. Over the years, he has demonstrated excellence in pedagogy, supervising more than 40 students across bachelor’s, master’s, and Ph.D. levels, while consistently engaging in advanced teaching in hematology, human genetics, and toxicology.

Contributions and Research Focus

Prof. Vrzal’s research spans a wide spectrum of molecular and cellular biology, with a special emphasis on ligand-activated nuclear receptors, drug metabolism, cytotoxicity, and cellular signaling. His investigations into the biological activity of natural and synthetic compounds, post-translational modifications of nuclear receptors, and applications of human intestinal organoids mark his innovative approach to biomedical research. His ongoing work in prostate cancer and anticancer therapeutics highlights the translational value of his research.

Impact and Influence

With 99 publications indexed in WoS, over 1,600 citations (excluding self-citations), and an H-index of 25, Prof. Vrzal has established a solid academic presence. His work has significantly contributed to understanding receptor-mediated mechanisms and their pharmacological implications, influencing both academic discourse and applied therapeutic research. As a grant holder and collaborator, he has led and co-led several national and international projects, including studies on MAP kinases, CYP3A4 enzyme regulation, and synthetic tryptamine derivatives for cancer treatment.

Academic Citations

His research is widely cited, reflecting the global relevance of his work. The citation record underscores his contributions to advancing pharmacology and toxicology, where his insights have informed subsequent studies on drug metabolism and receptor signaling. This recognition also highlights his influence on shaping research directions in biochemical and biomedical sciences.

Legacy and Future Contributions

Prof. Vrzal’s legacy lies in his dual commitment to advancing scientific research and nurturing the next generation of scholars. His supervision of numerous students and his long-standing dedication to teaching ensure knowledge transfer and academic continuity. Looking forward, his ongoing projects on anticancer therapeutics and cellular models hold promise for impactful discoveries in medicine and pharmacotherapy.

Conclusion

Prof. Dr. Radim Vrzal exemplifies the qualities of a dedicated researcher, mentor, and innovator. His academic trajectory, impactful research contributions, and sustained influence in molecular and biomedical sciences position him as a deserving candidate for recognition. His ability to bridge fundamental science with applied therapeutic research ensures that his future work will continue to make meaningful contributions to both academia and society.

Notable Publications

“Skin-targeted AhR activation by microbial and synthetic indoles: Insights from the AhaRaCaT reporter cell" 

  • Author: Radim Vrzal; Aneta Grycová; Aneta Vrzalová
  • Journal: Toxicology Letters
  • Year: 2025

"‏Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation" 

  • Author: Aneta Vrzalova; Radim Vrzal‏
  • Journal: Biochimie
  • Year: 2025

"Modulation of aryl hydrocarbon receptor activity by halogenated indoles" 

  • Author: Aneta Vrzalová; Radim Vrzal; Petr Nádvorník; Marek Šebela; Zdeněk Dvořák
  • Journal: Bioorganic and Medicinal Chemistry
  • Year: 2024

"Jasmone Is a Ligand-Selective Allosteric Antagonist of Aryl Hydrocarbon Receptor (AhR)" 

  • Author: Radim Vrzal; Adéla Marcalíková; Kristýna Krasulová; Lenka Zemánková; Zdeněk Dvořák‏
  • Journal: International Journal of Molecular Sciences‏
  • Year: 2023

"Monoterpenoid aryl hydrocarbon receptor allosteric antagonists protect against ultraviolet skin damage in female mice" 

  • Author: Karolína Ondrová; Iveta Zůvalová; Barbora Vyhlídalová; Kristýna Krasulová; Eva Miková; Radim Vrzal; Petr Nádvorník; Martina Kopečná; David Kopečný; Marek Šebela et al.
  • Journal: Nature Communications
  • Year: 2021

 

Zhengyang Guo | Metabolism Networks | Best Researcher Award

Published on by Network Science

Dr. Zhengyang Guo | Metabolism Networks | Best Researcher Award

Peking University Third Hospital | China

Author Profile 

Scopus

Early Academic Pursuits

Zhengyang Guo’s academic journey began with a strong foundation in the life sciences. He earned his Bachelor’s degree from the School of Basic Medical Sciences at Peking University, which provided him with comprehensive knowledge in biomedical sciences. His pursuit of higher education continued at the Department of Microbiology, Peking University, where he obtained his M.D. degree. This academic background not only reflects his commitment to advancing medical research but also highlights the interdisciplinary foundation that shaped his later contributions in oncology and immunology.

Professional Endeavors

Currently serving as an Assistant Professor at Peking University Third Hospital, Guo has dedicated his professional career to the study of tumor biology and clinical translational research. Alongside his teaching responsibilities, he actively contributes to developing cutting-edge techniques through his involvement in the immunology platform and guiding graduate students in experimental teaching. His professional endeavors balance research, teaching, and technological development, underlining his role as both a researcher and mentor.

Contributions and Research Focus

Dr. Guo’s research primarily centers on tumor epigenetics, tumor metabolism, and the tumor microenvironment. His innovative work investigates molecular mechanisms that influence cancer progression and therapeutic outcomes. Specifically, he has focused on targeting the enzyme SCD1 in combination with EZH2 inhibitors to enhance the efficacy of melanoma treatment and immunotherapy. His projects, supported by prestigious funding bodies such as the National Natural Science Foundation of China and Peking University Medicine Fund, reflect both the clinical relevance and scientific novelty of his work.

Impact and Influence

As an active contributor to the global scientific community, Guo holds membership in the Biophysical Society of China and the Chinese Society of Biochemistry and Molecular Biology. His expertise is recognized internationally, as he serves as a peer reviewer for high-impact journals including Experimental Hematology & Oncology, Cell Communication and Signaling, Apoptosis, and Lipids in Health and Disease. These engagements highlight his influence in shaping scientific dialogue and advancing standards in cancer research.

Academic Cites and Intellectual Property

Guo’s research impact extends beyond publications into intellectual property and patents. He is a co-inventor on multiple patents related to antitumor drug compositions involving EZH2 and SCD1 inhibitors, as well as novel approaches to treating liver cancer using diacylglycerol kinase γ. These patents underscore the translational potential of his work, bridging basic molecular research with therapeutic innovation. His contributions are already shaping new pathways in drug discovery and cancer therapy.

Legacy and Future Contributions

With a strong foundation of academic excellence, innovative research, and translational breakthroughs, Guo is poised to make long-lasting contributions to the field of oncology. His ongoing efforts in epigenetic regulation, tumor metabolism, and immunotherapy strategies hold promise for redefining cancer treatment paradigms. By mentoring future scholars and fostering collaborations across disciplines, he is actively building a legacy that will continue to influence both academia and clinical practice.

Conclusion

In summary, Dr. Zhengyang Guo exemplifies the qualities of a modern medical researcher-a scholar who bridges fundamental biology with clinical application. His journey from early academic pursuits to groundbreaking research in tumor biology reflects dedication, innovation, and leadership. With multiple funded projects, patents, and international recognition, his work significantly impacts the scientific community and promises future advancements in cancer treatment. His career trajectory positions him as a leading figure in biomedical research, with the potential to transform cancer therapy at both national and global levels.

Notable Publications

"3G Internet Diffusion and Secondary Education Attainment: Evidence of Opportunity Cost in Vietnam" 

  • Author: Trang Thi Pham; Bernardo Caldarola
  • Journal: Review of Development Economics
  • Year: 2025